NU553 Asthma Lecture Notes
Effective management of respiratory conditions relies on tailored pharmacological interventions, accurate diagnosis, and consistent patient education. Asthma and COPD treatments prioritize reducing airway inflammation and achieving bronchodilation using inhaled corticosteroids (ICS), long-acting beta-agonists (LABAs), and long-acting muscarinic antagonists (LAMAs). Pneumonia and tuberculosis management require targeted antimicrobial and multidrug therapies based on the pathogen and patient demographics. Furthermore, tobacco cessation utilizing a combination of nicotine replacement, non-nicotine medications, and behavioral counseling remains one of the most vital interventions to halt respiratory disease progression and improve overall survival.
Understanding and Managing Asthma
Asthma is a chronic inflammatory airway disease characterized by reversible airflow obstruction and hyperresponsiveness. Patients typically suffer from recurring episodes of wheezing, coughing, chest tightness, and shortness of breath. The overarching goal of asthma therapy is to achieve long-term symptom control while minimizing the risk of severe exacerbations. Disease severity is generally classified into mild intermittent, mild persistent, moderate persistent, and severe persistent categories, which dictate the stepwise approach to treatment.
Short-Acting and Long-Acting Beta-Agonists
Short-acting beta-agonists (SABAs), such as albuterol and levalbuterol, provide rapid bronchodilation by relaxing airway smooth muscle. They are commonly utilized as rescue inhalers for acute asthma attacks, exercise-induced bronchospasm, and temporary symptom relief. However, current global guidelines strictly advise against using a SABA alone as a long-term therapy, as it fails to address underlying airway inflammation and increases the risk of severe exacerbations.
For maintenance therapy, long-acting beta-agonists (LABAs) like salmeterol and formoterol are utilized to maintain bronchodilation for 12 hours or more. A critical clinical rule in asthma management is that LABAs must never be prescribed as a standalone treatment. They should always be combined with an inhaled corticosteroid to safely improve asthma control and reduce the risks associated with LABA monotherapy.
Inhaled Corticosteroids and LAMAs
Inhaled corticosteroids (ICS), such as fluticasone, budesonide, and beclomethasone, are the absolute foundation of persistent asthma management. Regular daily use of an ICS directly reduces airway inflammation, decreases the frequency of exacerbations and hospitalizations, and lowers the patient’s reliance on rescue inhalers. Patients are advised to rinse their mouths after each use to prevent oral candidiasis.
Long-acting muscarinic antagonists (LAMAs), including tiotropium and umeclidinium, block muscarinic receptors to produce sustained bronchodilation. While traditionally reserved for COPD, LAMAs are increasingly recommended as an add-on therapy for patients with moderate-to-severe asthma who remain uncontrolled despite optimized ICS and LABA therapy.
Current Treatment Guidelines
Modern asthma management utilizes a stepwise approach, requiring clinicians to regularly reassess symptom control and step therapy up or down accordingly. The Global Initiative for Asthma (GINA) promotes a six-step approach that heavily discourages SABA-only therapy, recommending ICS-containing treatments even for mild asthma. Specifically, GINA recommends as-needed low-dose ICS-formoterol for many patients. The National Asthma Education and Prevention Program (EPR) follows a similar five-step model that continually emphasizes inhaled corticosteroids for any persistent disease. Regardless of the guideline used, all patients should receive a personalized asthma action plan and education on proper inhaler technique.
Chronic Obstructive Pulmonary Disease (COPD)
COPD is a progressive respiratory disorder marked by persistent, non-reversible airflow limitation. The gold standard for diagnosis is spirometry; specifically, a post-bronchodilator FEV1/FVC ratio below 70% confirms persistent airflow obstruction. Treatment focuses on slowing disease progression, improving exercise tolerance, reducing exacerbations, and enhancing overall quality of life.
Clinical Presentation and Severity
Clinically, COPD often presents in two distinct phenotypes, though many patients exhibit overlapping features. Emphysema, historically described as “pink puffers,” is characterized by a barrel-shaped chest, pursed-lip breathing, and a thin body habitus. Chronic bronchitis, sometimes referred to as “blue bloaters,” presents with a chronic productive cough, cyanosis, and peripheral edema.
Disease severity is objectively classified using the patient’s FEV1 predicted percentage:
Mild: FEV1 > 80%
Moderate: FEV1 50–80%
Severe: FEV1 30–50%
Very Severe: FEV1 < 30% (or < 50% coupled with chronic respiratory failure)
Pharmacologic Therapy and Exacerbation Management
The pharmacological foundation of COPD management relies heavily on bronchodilators. LAMAs (like tiotropium and ipratropium) and LABAs (like salmeterol) are first-line maintenance medications used to reduce airflow obstruction and decrease exacerbation frequency. For patients with significant airflow limitation, combination bronchodilator therapy generally provides a superior improvement in lung function compared to monotherapy. Methylxanthines, such as theophylline, are rarely used today due to their narrow therapeutic index, need for frequent monitoring, and numerous drug interactions.
During acute COPD exacerbations, the standard of care includes a short course of systemic corticosteroids, typically prednisone 40 mg daily for 5 to 10 days. This shortens recovery time, improves lung function, and decreases hypoxemia. Long-term oral corticosteroids are generally avoided due to significant adverse effects. Additionally, supplemental oxygen therapy is indicated during acute hypoxemic exacerbations or for chronic use when a patient’s resting oxygen saturation falls below 88%, which has been shown to improve survival rates in severe cases.
Pneumonia Treatment Protocols
Pneumonia is an infection of the lung parenchyma caused by bacteria, viruses, fungi, or atypical organisms, presenting with fever, cough, leukocytosis, and abnormal chest imaging. It is important to note that chest radiographs may take four weeks or longer to normalize following clinical recovery.
Adult Community-Acquired Pneumonia
The treatment of community-acquired pneumonia (CAP) in adults is dictated by the presence of comorbidities, local antimicrobial resistance patterns, and individual risk factors. Patients with comorbidities or those at risk for drug-resistant Streptococcus pneumoniae are typically treated with a respiratory fluoroquinolone (such as levofloxacin or moxifloxacin) or a combination of a beta-lactam and a macrolide. Doxycycline serves as a viable alternative when appropriate.
Pediatric Pneumonia Management
Pediatric pneumonia treatment relies heavily on the age of the child, which often dictates the likely pathogen. In young infants (4 to 16 weeks), Chlamydia trachomatis is a primary consideration, and macrolides like azithromycin or erythromycin are utilized. In children younger than five, Streptococcus pneumoniae is the most common bacterial cause, making high-dose amoxicillin the treatment of choice, with ceftriaxone reserved for severe illness. For children older than five years, atypical organisms such as Mycoplasma pneumoniae become prevalent, and treatment shifts back to macrolides like azithromycin or clarithromycin.
Tuberculosis (TB) Management and Monitoring
Tuberculosis is a highly infectious disease caused by Mycobacterium tuberculosis, spread via airborne respiratory droplets. Management of this condition demands a rigorous, prolonged approach and careful patient education to ensure adherence and prevent antimicrobial resistance.
Active and Latent Infection Treatment
Treating active tuberculosis requires a prolonged multidrug regimen, commonly ranging from six to nine months. The standard first-line intensive phase includes Isoniazid (INH), Rifampin, Ethambutol, and Pyrazinamide.
Latent TB infection occurs when a patient shows evidence of infection without active symptoms or radiographic evidence. Treating latent TB with appropriate antimicrobial therapy is crucial, as it substantially reduces the risk of the infection progressing to active, transmissible disease.
Patient Monitoring and Safety
Due to the toxicity profile of TB medications, routine laboratory monitoring is mandatory. Clinicians must conduct baseline and follow-up assessments of liver function, bilirubin, serum creatinine, and complete blood counts. Monthly sputum cultures are required until they return negative. Patients taking isoniazid must be closely monitored for hepatitis and peripheral neuropathy; Vitamin B6 (pyridoxine) supplementation is routinely prescribed alongside INH to mitigate the risk of neurological side effects.
Evidence-Based Tobacco Cessation
Smoking cessation remains the single most important and effective intervention for improving respiratory health, increasing overall survival, and slowing the progression of diseases like COPD. Evidence-based pharmacologic treatments include nicotine replacement therapies (gum, lozenges, patches, and nasal sprays) as well as non-nicotine oral medications like bupropion and varenicline. Clinical data consistently demonstrates that combining these pharmacologic therapies with structured behavioral counseling produces the highest long-term quit rates.
Frequently Asked Questions
What is the difference between a SABA and a LABA?
A short-acting beta-agonist (SABA) provides rapid, immediate relief during an acute asthma attack and is used exclusively as a rescue inhaler. Conversely, a long-acting beta-agonist (LABA) provides sustained bronchodilation over 12 or more hours for daily maintenance therapy. In asthma management, a LABA must always be combined with an inhaled corticosteroid and never used as a standalone treatment.
Why are inhaled corticosteroids considered essential in asthma?
Inhaled corticosteroids are the cornerstone of asthma treatment because they directly treat the underlying mechanism of the disease. They reduce chronic airway inflammation, lower the rate of severe exacerbations, improve baseline lung function, and significantly decrease hospitalization rates.
How is COPD definitively diagnosed?
COPD is diagnosed objectively through spirometry testing. A post-bronchodilator FEV1/FVC ratio that falls below 70% confirms the presence of persistent, non-reversible airflow obstruction characteristic of the disease.
What medications are commonly used to treat tuberculosis?
The initial, intensive phase of tuberculosis treatment relies on a four-drug regimen to prevent bacterial resistance: isoniazid, rifampin, pyrazinamide, and ethambutol. This is followed by a scaled-back continuation therapy phase dictated by clinical guidelines and individual susceptibility testing.
References
Centers for Disease Control and Prevention. (2024). Smoking and tobacco use: Quitting smoking. https://www.cdc.gov/tobacco
Centers for Disease Control and Prevention. (2025). Tuberculosis (TB): Clinical care and treatment. https://www.cdc.gov/tb
Global Initiative for Asthma. (2025). Global strategy for asthma management and prevention. https://ginasthma.org
Global Initiative for Chronic Obstructive Lung Disease. (2025). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. https://goldcopd.org
NU553 Asthma Lecture Notes
Metlay, J. P., Waterer, G. W., Long, A. C., et al. (2019). Diagnosis and treatment of adults with community-acquired pneumonia. American Journal of Respiratory and Critical Care Medicine, 200(7), e45-e67. https://doi.org/10.1164/rccm.201908-1581ST
National Heart, Lung, and Blood Institute. (2020). 2020 focused updates to the asthma management guidelines. https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines